Sigma-Aldrich signs agreement to acquire Ace Animals

Sigma-Aldrich® (Nasdaq: SIAL) today announced it has signed an agreement to acquire Ace Animals, Inc., a Berks County, PA.-based provider of high quality research rodents to the biomedical industry. Ace Animals (www.aceanimals.com), a commercial rodent breeder established in 1973, offers high quality products and contract breeding services, and will operate as part of Sigma Advanced Genetic Engineering (SAGE™) Labs (www.sageresearchmodels.com), a Sigma® Life Science initiative. Terms and conditions of the agreement were not disclosed.  Closing is expected shortly.

The acquisition will enhance SAGE Labs' current rat and mouse breeding capabilities, primarily used in the development and characterization of its unique, next-generation 'Knockout' and 'Knockin' rat models featuring specific gene deletions, insertions, repressions and modifications created using proprietary CompoZr™ Zinc Finger Nuclease (ZFN) technology. In addition, Ace Animals' strategic location in Pennsylvania is expected to greatly enhance distribution of SAGE Labs models to key sites within the United States bio-pharma industry.

Through the acquisition, SAGE Labs plans to offer a significantly increased portfolio of products and services, including a number of 'wild type' (that is, animals that have not been genetically modified) rats and mice, including Swiss Webster, Sprague Dawley, ICR, Balb/c, C57BL/6 and Cotton Rats. SAGE Labs will be positioned to offer contract breeding services, considered a natural extension of its current SAGEspeed™ animal creation service.  Concurrently, Ace Animals, Inc.'s customers are expected to benefit from access to the industry-leading genetic engineering platforms offered through Sigma's SAGE labs.

SAGE Labs is the premier resource for genetically modified rodent disease models and markets its exclusive SAGEspeed™ Custom Model Development program for the creation of knockout mouse or rat models in as little as five months. The group is also developing their catalog of knockout rat models across a number of research fields, including Neurobiology, Toxicology, Cardiology and Immunology.

"With the Ace Animals acquisition, SAGE Labs will be in a better position to offer a greater number of models with the goal of helping researchers understand the functional significance of genes and their relationships to human diseases," said Dr. Edward Weinstein, Director of SAGE Labs. "In vivo models of human disease states serve as more predictive proxies to the human condition, and therefore are instrumental to the discovery of novel and powerful therapeutics."